Effects of tislelizumab on health-related quality of life in patients with recurrent or metastatic nasopharyngeal cancer.
Yunpeng YangJianji PanNianyong ChenYe GuoXiaoming HuangYanjie WuShiangjiin LeawFan BaiYu WangNa ZhaoBoxiong TangGisoo BarnesPublished in: Head & neck (2024)
The current findings, along with improved survival and favorable safety, suggests that tislelizumab + chemotherapy represents a potential first-line treatment for recurrent or metastatic nasopharyngeal cancer.